Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPI-371153 in Advanced Solid Tumors or Relapsed/Refractory Lymphoma
NCT05341557Phase 1Recruiting
- Sponsor
- Betta Pharmaceuticals
- Start
- Aug 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BPI-371153 in solid tumor (advanced stage), lymphoma, non-small cell lung cancer (NSCLC) and 1 more (2 arms), sponsored by Betta Pharmaceuticals. Primary endpoints: Adverse Events at 24 months and Recommended Phase 2 Dose at 24 months. Started Aug 2022; status: recruiting.
02
Drugs
BPI-371153
03
Conditions
solid tumor (advanced stage)lymphomanon-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05341557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05341557.